A successful initiation of treatment of Hodgkin's lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immunodeficiency virus and hepatitis B.

Sindhusha Veeraballi,Kok Hoe Chan,Jihad Slim,Hamid Shaaban,Gunwant Guron

A successful initiation of treatment of Hodgkin's lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immunodeficiency virus and hepatitis B.

2021

Sindhusha Veeraballi
Kok Hoe Chan
Jihad Slim
Hamid Shaaban
Gunwant Guron

IntroductionHodgkin lymphoma is a highly curable lymphoproliferative malignancy with an overall relative survival rate of 87.4%. It is characterized by multinucleated Reed–Sternberg cells which are...

Keywords:

Cancer research
co infection
Lymphoma
Fulminant hepatic failure
adriamycin bleomycin vinblastine dacarbazine
Medicine
Malignancy
dose reduction
Hodgkin's lymphoma
Hepatitis B

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations